Changes in Awake Cystometry and Expression of Bladder β-adrenoceptors after Partial Bladder Outlet Obstruction in Male Rats

박민구,박홍석,이정구,김형지 대한배뇨장애요실금학회 2010 International Neurourology Journal Vol.14 No.3

Purpose: To explore possible changes in awake cystometry and expression of beta-adrenoceptors (ARs) as a cause for bladder dysfunction in a male rat model of partial bladder outlet obstruction (pBOO). Materials and Methods: Awake cystometry was performed in rats with pBOO (16) and sham-operated rats (16), 8 weeks after the operation. The expression of mRNA and protein of β-ARs was assessed by real-time PCR and western blot. Results: The bladders with pBOO (1030mg) were increased compared to those in control rats (230mg). In the cystometric studies, the maximum intravesical pressure significantly increased in the pBOO group compared to control group rats (p=0.001). The time to reach maximal intravesical pressure during micturition in the pBOO group was significantly longer than the sham group (p=0.003). The frequency of non-void contraction in the pBOO group was significantly more than the sham group (p=0.006). The mRNA expressions of β2- and 3-ARs were increased insignificantly in pBOO group compared to sham group. The data of pBOO group expressed as folds of corresponding expression in sham group were 1.28 and 1.46 respectively in β2- and 3-ARs. Compared to the sham groups, the density of 60Kda protein band recognized by β2-AR antibodies and the density of 45Kda protein band recognized by β3-AR antibodies were higher in the bladder from pBOO group rats. Conclusion: PBOO of male rats increase the maximal intravesical pressure and contraction time during micturition and the frequency of non-void contraction as well as weight of bladder. The expression of β2- and 3-ARs subtypes was increased insignificantly compared to sham operated group. This study demonstrates that the changes of cystometric or non-void contraction parameters in pBOO is one of the pathophysiologic processes potentially associated with the alterations of bladder β-ARs.

한국 남성에서 남성갱년기 증후군의 인지도에 관한 조사 -40대 이상을 대상으로 한 연령별 설문 조사-

박민구,이종,강석호,문두건,김제종,강승철,이태원 대한남성과학회 2007 The World Journal of Men's Health Vol.25 No.1

재발성 요로감염에 대한 예방적 항생제 요법

박민구,조대연 대한요로생식기감염학회 2014 Urogenital Tract Infection Vol.9 No.1

Recurrent uncomplicated urinary tract infection (UTI) is a common problem in women, causing considerable morbidity and expense, and is a management burden for clinicians. In management of recurrent UTI, non-antimicrobial approaches to prevention of UTI, such as behavioral modifications should first be tried as a way of minimizing antimicrobial exposure, however, antimicrobial treatment of prophylaxis may be necessary in those who continue to have recurrences. Continuous antimicrobial prophylaxis, post-coital prophylaxis with low dose antimicrobials, and intermittent self-treatment with antimicrobials have all been shown to be effective in prevention of recurrent uncomplicated UTIs. The decision regarding which approach to use for prophylaxis depends on the frequency and pattern of recurrence and the patient’s preference to commit to a specific method. The risk of adverse events and the plan for pregnancy should be considered before starting any regimen of antimicrobial prophylaxis. The susceptibility of the organisms causing the previous UTIs and history of the patient’s drug allergies should be considered before selection of antimicrobials. Before initiation of any prophylaxis regimen, eradication of a previous UTI should be confirmed by a negative urine culture. Continuous antimicrobial prophylaxis is usually used for long periods, thus likely contributing to the widespread problem of antimicrobial resistance. Post-coital prophylaxis and self-treatment approach result in less antimicrobial use, but should be used in the appropriate settings.

Diagonally-reinforced Lane Detection Scheme for High-performance Advanced Driver Assistance Systems

박민구,유경호,박윤호,이영주 대한전자공학회 2017 Journal of semiconductor technology and science Vol.17 No.1

In this paper, several optimizations are proposed to enhance the quality of lane detection algorithms in automotive applications. Considering the diagonal directions of lanes, the proposed limited Hough transform newly introduces image-splitting and angle-limiting schemes that relax the number of possible angles at the line voting process. In addition, unnecessary edges along the horizontal and vertical directions are pre-defined and removed during the edge detection procedures, increasing the detecting accuracy remarkably. Simulation results shows that the proposed lane recognition algorithm achieves an accuracy of more than 90% and a computing speed of 92 frame/sec, which are superior to the results from the previous algorithms.

테스토스테론결핍증후군 남성에서 경구용 테스토스테론제와 경피용 테스토스테론 겔의 효과 비교

박민구,정승민,안순태,강재일,신수환,박태용,배재현,김제종,문두건 대한남성과학회 2010 The World Journal of Men's Health Vol.28 No.3

Purpose: Oral testosterone undecanoate and transdermal testosterone gel are the testosterone formulas widely prescribed as hormonal replacement for tesosterone deficiency syndrome (TDS) in male patients. We evaluated the changes in serum testosterone level and the effects of these medicines. Materials and Methods: The medical records of 162 patients who were diagnosed with TDS based on serum testosterone (<2.55 ng/ml) and prescribed testosterone formula were analyzed retrospectively. In the 111 patients of group I, tablets of oral testosterone undecanoate were initially given. If the follow up serum testosterone level had not increased enough, the dosages were increased up to 6 tablets. In the 51 patients of group II, one pack of transdermal testosterone gel (5 gm) daily without dosage adjustment was prescribed. Statistical analysis was done to identify any correlations among age, initial and final aging male’s symptoms scale (AMS) score, initial, peak and final testosterone level, and duration of therapy. Results: The mean ages of group I and II were 53.4±14.5 and 55.2±11.9, respectively (p>0.05). The initial and final testosterone levels of the two groups were not significantly different. However, the peak level during treatment was significantly higher in group II (p<0.05). The maximal increment of testosterone level was also significantly higher in group II. Initially, group II reached its peak testosterone level earlier than group I. The final serum levels were not significantly different after adjustment of dosages in group I. Testosterone replacement significantly decreased the AMS scales in both groups. Conclusions: Both oral testosterone undecanoate and transdermal testosterone gel improved the serum testosterone level and symptom score for those with TDS. Transdermal testosterone gel may reach the peak serum testosterone level faster than oral testosterone undecanoate. Large prospective studies are required to assess the precise role of testosterone replacement therapy.

검역적 소독기술의 현황과 국내 방제에 대한 적용

박민구 한국농약과학회 2023 한국농약과학회 학술발표대회 논문집 Vol.2023 No.11

성욕감퇴가 있으나 정상 혈청 테스토스테론치를 가진 발기부전 환자에서 PDE5 차단제 단독요법과 Trazodone과의 병합요법의 비교

박민구,진명헌,배재현,김제종,문두건 대한남성과학회 2008 The World Journal of Men's Health Vol.26 No.1

Purpose: This study was done to assess the therapeutic effect of trazodone, an antidepressant agent in combination with sildenafil in patients with erectile dysfunction (ED) and decreased libido with normal serum testosterone level. Materials and Methods: From March 2005 to February 2006, 90 patients with ED complaining of decreased libido but whose serum testosterone level was within normal range were screened and enrolled in this study. The subjects were randomly treated by sildenafil only (group 1) and combination of sildenafil with trazodone (group 2). Patients received trazodone for at least 3 consecutive months, with daily doses starting at 50 mg. By intention-to-treat basis, the period of study was extended by 9 month. The intention-to-treat population included 39 sildenafil recipients and 35 sildenafil with trazodone recipients. The patients were asked to make up two questions, Q1: ‘Did you experience improvement of erection after treatment?’ and Q2: ‘Did you experience improvement of libido after treatment?’ and the change of International index of erectile function (IIEF) scores before and after the treatment were analyzed to assess the efficacy of treatment. Results: After 3 month treatment period, 70% of group 1 and group 2 answered ‘yes’ to Q1. Twenty seven percents of group 1 and 51% of group 2 answered ‘yes’ to Q2 and 20% of group 1 and 24% of group 2 answered ‘yes’ to both Q1 and Q2. In the intention-to-treat population, seventy-two percents of group 1 and 71% of group 2 answered ‘yes’ to Q1 and 28% of group 1 and 52% of group 2 answered ‘yes’ to Q2, 21% of group 1 and 26% of group 2 answered ‘yes’to both Q1 and Q2. The change of IIEF scores before and after the treatment at 3 month and 9 month showed similar results. Both group 1 and group 2 showed significant improvement on scores of IIEF-5 and question 15 of IIEF after treatment (p<0.01). Meanwhile, only group 2 showed significant improvement on question 11 and 13 of IIEF after the treatment compared to group 1 (p<0.05). Two patients with high dose of trazodone complained of headache and drowsiness, but the symptoms disappeared by dose reduction. Conclusions: The combination therapy of trazodone with sildenafil increased libido and sexual satisfaction on patients with ED. Therefore, combination of trazodone with sildenafil might be considered in ED patients of decreased libido with normal serum testosterone level rather than sildenafil monotherapy.

검역용 MB 대체물질 연구 현황

박민구,정우창,허종영,성보경,이병호 한국농약과학회 2006 한국농약과학회 학술발표대회 논문집 Vol.- No.-

PDE5 차단제 비반응군에서 테스토스테론과 PDE5 차단제 병합요법의 효과

박민구,박세홍,김제종,문두건,고기원,함병국 대한남성과학회 2009 The World Journal of Men's Health Vol.27 No.1

Purpose: The aim of this study was to evaluate the efficacy of a combination therapy with PDE5 inhibitor and testosterone replacement therapy in erectile dysfunction patients with testosterone deficiency syndrome (TDS) after failure of PDE5 inhibitor mono-therapy. Materials and Methods: From March 2004 to July 2008, we evaluated 38 men (aged 38 to 69 years) who showed no response to PDE5 inhibitor therapy at the maximal recommended dose and they had testosterone levels less than 350ng/dL. Testosterone replacement therapy (TRT) was subsequently started with injectable testosterone undecanoate (NEBIDOⓇ) or transdermal testosterone (TestogelⓇ) in those patients. They received TRT during an 18-week period. After 14 weeks of TRT alone, PDE5 inhibitor was added to the TRT for an additional 4 weeks. After treatment, we evaluated the patients’ sexual function, which was primarily based on the International Index of Erectile Function (IIEF), and the serum testosterone levels. Results: All patients showed elevated serum testosterone levels after TRT (range: 212 to 662ng/dl, mean level: 362.19 ng/dl). At week 18, almost all of the men reported improved potency with combination therapy. After treatment, the mean total IIEF score and each sub-domain score were increased significantly compared to the baseline score. Conclusions: Testosterone replacement therapy combined with PDE5 inhibitor may be beneficial in improving the erectile function in testosterone deficiency syndrome patients with erectile dysfunction and who are unresponsive to PDE5 inhibitor alone.

쿠웨이트 원유오염토양 생물세척 처리

박민구,이성종,하태상,강구영 대한환경공학회 2017 대한환경공학회 학술발표논문집 Vol.2017 No.11